BioLASCO Taiwan Co., Ltd. (TPEX:6662)
29.75
+0.10 (0.34%)
At close: Feb 11, 2026
BioLASCO Taiwan Revenue
BioLASCO Taiwan had revenue of 63.22M TWD in the quarter ending September 30, 2025, a decrease of -8.04%. This brings the company's revenue in the last twelve months to 277.12M, down -4.65% year-over-year. In the year 2024, BioLASCO Taiwan had annual revenue of 292.50M with 10.49% growth.
Revenue (ttm)
277.12M
Revenue Growth
-4.65%
P/S Ratio
2.74
Revenue / Employee
3.05M
Employees
91
Market Cap
759.40M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 292.50M | 27.78M | 10.49% |
| Dec 31, 2023 | 264.72M | 28.81M | 12.21% |
| Dec 31, 2022 | 235.91M | 8.33M | 3.66% |
| Dec 31, 2021 | 227.58M | -71.30M | -23.86% |
| Dec 31, 2020 | 298.88M | -47.81M | -13.79% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Level Biotechnology | 753.30M |
| Taiwan Advance Bio-Pharmaceutical | 371.86M |
| TCI GENE | 324.73M |
| Lukas Biomedical | 180.32M |
| NatureWise Biotech & Medicals | 180.29M |
| Vectorite Biomedical | 67.90M |
| Holy Stone Healthcare | 47.51M |
| Neith | 39.35M |